Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Bolt Biotherapeutics Director Brian O'Callaghan was granted stock options for 5,000 shares.

Summary

• Brian O'Callaghan, a Director at Bolt Biotherapeutics, Inc., was granted stock options on June 10, 2026.
• The options are for 5,000 shares of common stock with an exercise price of $4.43 per share.
• These options are exercisable and expire on June 9, 2036.
• Vesting is scheduled for June 9, 2027, or the day before the next annual stockholder meeting, contingent on continued service.
• The options will vest in full upon a change in control of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation and incentive mechanism for a company director rather than a significant financial event.

Positives

• Director O'Callaghan's acquisition of stock options aligns his interests with those of shareholders.
• The vesting schedule incentivizes continued service and long-term commitment to the company.
• The full vesting upon a change in control provides potential upside for the director in a significant corporate event.

Risks

• The value of the stock options is subject to the future performance of Bolt Biotherapeutics' stock price.
• If the director's service is not continuous, the options may not fully vest as planned, excluding the change in control provision.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and potential change in control events. The vesting schedule indicates a commitment to the company's long-term prospects.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology sector to attract and retain talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The alignment of director incentives with company performance may positively influence long-term shareholder value.
• Employees: The company's ability to retain key personnel like directors is crucial for operational stability and future growth.
• Management: The stock options serve as a performance-based incentive for the director.

Next Steps

• Director O'Callaghan will continue to provide service to Bolt Biotherapeutics, Inc.
• The stock options will vest according to the schedule outlined, with full vesting upon a change in control.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Insider Trading